Navigation Links
GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
Date:1/6/2009

ST. JOSEPH, Mich., Jan. 6 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and high quality manually curated databases for systems biology and pathway analysis, today announced that Bayer Schering Pharma AG has renewed its MetaCore licenses for another three years. Bayer Schering Pharma has programs for cancer, cardiovascular diseases and gynecological therapies and GeneGo has good coverage of these diseases and others. GeneGo is also in the process of building disease specific platforms in cancer and the cardiovascular area that include blueprint pathway maps for the disease, processes and mechanisms as well as offering public domain experimental data and disease ontologies.

"Bayer Schering Pharma was one of our first customers and we appreciate their loyalty," said Julie Bryant, Vice President of Business Development at GeneGo. "MetaCore is widely used in Bayer in multiple departments including bioinformatics, oncology, cardiology and women's health for data mining and analysis of multiple omics experimental data such as gene expression and proteomics."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.1(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.1(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at http://www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
2. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
3. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
4. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
5. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
6. Unilever Extends Their GeneGo MetaCore License
7. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
8. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
9. GSK Extends GeneGo License and Adds New Products
10. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
11. GeneGo Integrates With Cytoscape
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... 1, 2017  Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... to the life sciences industry, today announced the launch ... reproductive health market. CryoStork SM Next Flight Out ... for reproductive health patients, providing express transportation across ... for reproductive health commodities such as sperm, eggs, embryos ...
(Date:3/1/2017)... SHANGHAI , March 1, 2017 ... Cork based Biotechnology Company and HD ... discovery Contract Research Organization (CRO), announced today that ... and provide new assay technologies for preclinical drug ... access to Luxcel,s state-of-the-art assays and technologies for ...
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... ... , ... Surface Plasmon Resonance (SPR) is a widely-used, label-free technique to characterize ... changes in the dielectric properties of the medium close to a metal surface. ... to 300 nm above the metal surface (Au) and thus by the material absorbed ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):